BAT6026, a novel anti-OX40 antibody with enhanced antibody dependent cellular cytotoxicity effect for cancer immunotherapy

OX40 (CD134), a member of the TNF receptor superfamily, is a widely studied costimulatory immune checkpoint. Several OX40 agonistic antibodies are in the clinical stage for cancer treatment, among which PF-04518600 is the leader and currently in phase II trial. It has been recognized that one potent...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Shizhong, Zheng, Dandan, Liu, Xiong, Mei, Xiong, Zhou, Congcong, Xiao, Cuizhen, Qin, Chao, Yue, Haitao, Lin, Jian, Liu, Cuihua, Li, Shengfeng, Yu, Jin-Chen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10421724/
https://www.ncbi.nlm.nih.gov/pubmed/37576888
http://dx.doi.org/10.3389/fonc.2023.1211759

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10421724/
https://www.ncbi.nlm.nih.gov/pubmed/37576888
http://dx.doi.org/10.3389/fonc.2023.1211759

Ejemplares similares